Lexicon Pharmaceuticals (LXRX) was Reiterated by Wedbush to “Outperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 31 from a previous price target of $30 . Wedbush advised their investors in a research report released on Aug 5, 2016.
Many Wall Street Analysts have commented on Lexicon Pharmaceuticals. Citigroup Initiated Lexicon Pharmaceuticals on Aug 2, 2016 to “Buy”, Price Target of the shares are set at $21.
On the company’s financial health, Lexicon Pharmaceuticals reported $-0.37 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.38. The company had revenue of $20.09 million for the quarter, compared to analysts expectations of $14.77 million. The company’s revenue was up 5186.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.27 EPS.
Lexicon Pharmaceuticals opened for trading at $15.96 and hit $16.74 on the upside on Thursday, eventually ending the session at $16.51, with a gain of 2.42% or 0.39 points. The heightened volatility saw the trading volume jump to 7,48,041 shares. Company has a market cap of $1,715 M.
In a different news, on Jun 8, 2016, James F Tessmer (VP, Finance & Accounting) sold 1,500 shares at $15.00 per share price.
Lexicon Pharmaceuticals Inc. (Lexicon) is a biopharmaceutical company. The Company is focused on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate is an orally delivered small molecule drug candidate as a treatment for carcinoid syndrome. It has completed two Phase II clinical trials and is conducting a single Phase III clinical trial of telotristat etiprate in carcinoid syndrome patients. The Company’s sotagliflozin is an orally delivered small molecule drug candidate as a treatment for type 1 and type 2 diabetes. The Company has completed two Phase II clinical trials of sotagliflozin in type 2 diabetes patients and an additional clinical trial of sotagliflozin in type 2 diabetes patients with renal impairment. It has also completed a Phase II clinical trial of sotagliflozin in type 1 diabetes patients.